22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment ...
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...
23 November 2022 - Report will be subject of CTAF meeting in June 2023; draft scoping document open to public ...
2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...
20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years. ...
20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...
20 October 2022 - Unsupported Price Increase” final report based on drugs identified through SB-17, the California drug price transparency law. ...
11 October 2022 - State law makers, like their federal counterparts, are focused on addressing the high and growing cost of ...
17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...
12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...
11 October 2022 - Excitement is building about a new generation of drugs that tout the ability to help adults ...
11 October 2022 - Registration now open for October 19 “Early Insights” webinar. ...
5 October 2022 - Report will be subject of Midwest CEPAC meeting in April 2023; Draft Scoping Document open to ...